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STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF 
HAEMORRHOIDAL PROLAPSE—COMPARISON OF HTA REPORTS, FOR 
TWO ITALIAN REGIONS
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OBJECTIVES: Surgical management of Haemorrhoidal Disease includes Milligan-
Morgan (MM) haemorrhoidectomy and Stapled Haemorrhoidopexy (PPH). Scope of 
work was to compare HTA Reports for PPH vs. MM (especially cost and budget 
impact analyses) for two Italian Regions: Lombardia and Toscana. METHODS: Lit-
erature search; identiﬁcation of the surgical course (intervention, hospital admission) 
and global course (clinical evaluation, surgical phase, follow-up) at the local hospital 
level; micro-costing for PPH vs. MM at 3 hospitals per Region; comparison of direct 
medical costs, reimbursement tariffs and budgetary impact in 2008 Euro values. 
RESULTS: PPH surgical pattern generates costs to Hospitals of a2,306 and a2,177/
case, respectively in Lombardia and Toscana; MM surgery costs are a1558 and 
a1277/case, respectively. Higher unitary costs of personnel and operating theatre in 
Lombardia drive higher surgical intervention costs, irrespective of procedure type. 
Whereas hospital admission costs were similar for PPH (a698 vs a638), the gap 
between Lombardia and Toscana widens for MM hospitalization costs (a812 vs a638), 
because of longer length of stay in full admission setting. The Lombardia DRG158 
tariff (a1209) is not sufﬁcient to recap costs of both alternatives, whilst the Toscana 
tariff (a1400) is remunerative only for MM, but not when applying higher levels 
of operating theatre unit cost. The global course generates costs of a2532 (PPH-
 Lombardia) and a2400 (PPH-Toscana) vs a1781 (MM-Toscana) and a1527 
(MM-Toscana). Sensitivity analyses on literature data conﬁrmed the robustness of 
basecase results. Budget impact analysis, based on regional statistics for haemorrhoidal 
surgery and suggested extra-tariffs for PPH, estimated the need for additional 
funding ranging 1.7%–16% for Lombardia and 2.2%–20.4% for Toscana, over the 
current Regional expenditure. CONCLUSIONS: Analysis of management courses 
showed the inadequacy of current regional funding for PPH and MM. Current region-
alization of the Italian NHS prompts for implementation of HTA at the Regional 
level.
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COMPLIANCE WITH ANTIPSYCHOTIC DRUGS AND 
HOSPITALIZATION: A NESTED CASE-CONTROL ANALYSIS IN A 
COHORT OF PEOPLE WITH SCHIZOPHRENIA
Moisan J, Grégoire JP
Université Laval, Québec, QC, Canada
OBJECTIVES: To assess the association between compliance with antipsychotic drug 
therapy and mental health-related hospitalization in people with schizophrenia. 
METHODS: A nested case-control study using the Quebec Health Insurance Board 
databases. The source cohort was made of people with schizophrenia who initiated 
an antipsychotic treatment between January 1, 2000 and March 31, 2007. Cases were 
cohort members who were hospitalized for a mental health-related problem during 
their follow-up period. Five matched (for sex, age and year of treatment initiation) 
controls were selected using density sampling method thus allowing a control’s 
 observation period to equal its case’s period. Compliance was assessed using the 
medication possession ratio (MPR). A paired multivariate logistic regression model 
was used to calculate adjusted odds ratios (OR). Co-variates included: mental health 
co-morbidities, patient characteristics at treatment initiation; antipsychotics and other 
drugs used as well as health services used during the observation period and current 
use of any antipsychotic at the end of the observation period. RESULTS: A total of 
2429 cases were identiﬁed and matched to 11,988 controls. Compared to individuals 
with a MPR q 80%, those with a MPR q 40% and 80% (OR: 1.4; 95% conﬁdence 
interval (CI): 1.1–1.7) and those with a MPR  40% (OR: 1.9; CI: 1.5–2.4) were more 
likely to be hospitalized. Were also more likely to be hospitalized: past antipsychotic 
users (OR: 1.4; CI: 1.1–1.7), those with low SES (OR: 1.3; CI: 1.2–1.4)) and those 
with more medical visits (2nd tertile: OR: 1.5; CI: 1.3–1.7, 3rd tertile: OR: 2.0; 
CI: 1.8–2.3). Likewise, having bipolar disorder (OR: 1.7; CI: 1.4–2.0) as well as 
having another psychosis diagnosis (OR: 1.4; CI: 1.2–1.7) increase the likelihood of 
hospitalization. CONCLUSIONS: Among people with schizophrenia, compliance 
with antipsychotic treatment does inﬂuence the risk of hospitalization.
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EVIDENCE FOR SSRI IN THE TREATMENT OF DEPRESSION: EARLY 
KNOWLEDGE GAIN—LATE CONSEQUENCES IN ROUTINE CARE?
Gothe H, Klein S, Storz P, Haeussler B
IGES Institut GmbH, Berlin, Germany
OBJECTIVES: This study aims to determine since when the evidence on the two most 
important groups of antidepressants SSRI and TCA could be valued as a sufﬁcient 
basis for medical decision making regarding the preference for one of them. Further-
more, it was analyzed whether the utilization of SSRI in Germany from this point 
onward was adequate and to what extent health gains might have been foregone due 
to a limited use of SSRI. METHODS: To determine since when the beneﬁcial effect 
of SSRI was known, cumulative metaanalyses of RCT derived from systematic reviews 
were conducted. The evidence base was considered as established, when signiﬁcant 
(5%-level) results favoring SSRI or TCA regarding two main outcome criteria (anti-
depressive efﬁcacy and treatment termination due to side-effects) were observed. 
 Utilization ﬁgures for SSRI and epidemiological estimates were taken from published 
sources. RESULTS: Findings on n  4031 patients of 31 studies on the antidepressive 
efﬁcacy from 1983 to 2001 could be considered. The cumulative metaanalysis showed 
no signiﬁcant difference between SSRI and TCA regarding the antidepressive efﬁcacy 
(RR 0.05; 95%-KI 0.01–0.12). On the other hand, in the course of time, SSRI were 
consistently superior regarding unwanted side-effects since 1985 (RR 0.69; 95%-KI 
0.62–0.77). CONCLUSIONS: Regarding the comparison of the efﬁcacy of both sub-
stance groups, our ﬁndings are in line with the common clinical appraisal. The supe-
riority of SSRI in terms of lower rates of treatment termination has become known 
in the mid 1980s. The analysis of the utilization data suggests a considerable delay in 
the consequences of this appreciation for routine care. Factors like cost considerations 
and lack in knowledge dissemination might have contributed to this phenomenon. 
Limitations of the present analysis are primarily associated with uncertainties of 
 epidemiological estimates and the application of study results to the entire patient 
population.
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OVERCOMING THE CHALLENGES OF MODELLING SCHIZOPHRENIA:  
A UK CASE STUDY OF THE COST-EFFECTIVENESS OF OLANZAPINE 
LONG-ACTING INJECTION VS. RISPERIDONE LONG-ACTING 
INJECTION
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OBJECTIVES: Schizophrenia is a complex and heterogeneous psychiatric disorder        
with usual onset in early adulthood leading to a lifetime of morbidity and chronic 
disability that affects a person’s ability to perceive, think and feel. The disease hetero-
geneity and chronic course presents signiﬁcant challenges for realistic economic model-      
ling. We present a cost-effectiveness model of schizophrenia applied to the UK, which 
overcomes the limitations of previous modelling techniques. METHODS: Given the 
heterogeneous and progressive nature of schizophrenia, accurate modelling needs to 
capture patient history and, in particular, the complex interactions between treatment 
discontinuation and relapse, and the impact of past relapses on the risk of future 
relapse. For these reasons, a discrete event simulation (DES) model was built compar-
ing the cost-effectiveness of olanzapine long-acting injection (OLAI) against risperi-
done long-acting injection (RLAI). The model considered a real-world patient 
population utilising data from real-world sources such as open-label studies rather 
than randomised controlled trials. An indirect comparison was used to calculate 
relapse and treatment discontinuation rates. Key outcomes of interest included relapse, 
discontinuation, treatment switching, side effects, quality-adjusted life years, and 
treatment and resource use costs. RESULTS: The DES model captured outcomes that 
other modelling techniques would struggle to achieve. Among these were patient time 
on/off different treatments, occurrence of side effects including post-injection syn-
drome, and the number of relapses and treatment discontinuations. By modelling a 
real-world patient population, the evaluation generated patient-level ﬁndings directly 
relevant to clinical practice and accentuated the beneﬁts of OLAI for reducing the risk 
of treatment discontinuation and in turn relapses. CONCLUSIONS: Key modelling 
challenges for schizophrenia include capturing patient history and time-dependent 
variables such as relapse and discontinuation. Real-world modelling to inform deci-
sion-making is growing in importance, and therefore requires the application of 
advanced simulation techniques.
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A SYSTEMATIC REVIEW OF THE REAL-WORLD STUDY EVIDENCE 
COMPARING THE SAFETY AND TOLERABILITY OF DONEPEZIL, 
RIVASTIGMINE AND GALANTAMINE FOR THE TREATMENT OF MILD 
TO MODERATE ALZHEIMER’S DISEASE
Lockhart I1, Mitchell S2, Kelly S3
1Pﬁzer Limited, Tadworth, UK, 2Abacus International, Bicester, UK, 3Pﬁzer, Tadworth, Surrey, 
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OBJECTIVES: The acetylcholinesterase inhibitors (ChEIs) donepezil, rivastigmine and 
galantamine are recommended for symptomatic treatment of mild to moderate 
Alzheimer’s Disease (AD). Despite AChEI efﬁcacy being demonstrated in randomised 
clinical trials (RCTs), this study design has limited validity in relation to real-world 
patient care. Observational studies of routine patient care can be valuable sources of 
adverse event (AE) data in chronic conditions such as AD. A systematic review was 
undertaken to compare the safety of the AChEIs in treating AD in routine clinical 
care. METHODS: Cochrane Library, MEDLINE, and EMBASE searches were con-
ducted together with searches of selected bibliographies and conference proceedings 
to identify head-to-head, non-randomised AChEI studies. Two reviewers indepen-
dently extracted data from relevant articles. RESULTS: Twelve studies (N  6 prospec-
tive; N  6 retrospective) met the pre-speciﬁed inclusion criteria. Due to study design 
heterogeneity, a narrative data analysis was conducted. Four studies reporting total 
AE data found consistently fewer AEs in donepezil versus other AChEI patients, the 
difference being statistically signiﬁcant in the largest study (N  5462; p  0.001). In 
three of four studies, fewer donepezil-treated patients withdrew due to AEs compared 
to patients receiving the other two AChEIs, with a statistically signiﬁcant difference 
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reported in the largest study (N  407; p  0.01). In four studies reporting total 
 gastrointestinal (GI) AE data, donepezil was consistently associated with a lower 
incidence of GI AEs compared to rivastigmine, with three of these reporting a lower 
incidence for donepezil compared to galantamine. In the largest study reporting 
total GI AEs (N  5462), the incidence was donepezil 6%, rivastigmine 14%, and 
galantamine 24%. In all studies, low numbers of CNS and cardiovascular AEs 
were recorded, with similar incidences of events found across the different AChEIs. 
CONCLUSIONS: In routine clinical settings, mild to moderate AD patients who 
received donepezil had fewer total and GI AEs versus patients treated with rivastigmine 
or galantamine.
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USING TREEMAPS TO ASSESS PHYSICAL COMORBIDITY RISK IN 
PATIENTS WITH BIPOLAR DISORDER
Marder WD1, Stranges E2, Houchens B3, Coffey R4, Wang SS1, Schabert L3, Kassed C4, 
Mark TL5
1Thomson Reuters, Cambridge, MA, USA, 2Thomson Reuters, Evanston, IL, USA, 3Thomson 
Reuters, Santa Barbara, CA, USA, 4Thomson Reuters, Washington, DC, USA, 5Thomson 
Healthcare, Inc, Washington, DC, USA
OBJECTIVES: Research has shown bipolar patients are at greater risk for somatic 
illnesses than the rest of the population. This study assesses the incidence and relative 
risk (RR) of physical comorbid disease among patients with bipolar disorder. 
METHODS: A large US longitudinal claims database and medical episode grouping 
software was used to construct disease speciﬁc episodes of care for the years 2006–
2007. The case population consisted of individuals 65 years with an episode of bipolar 
disorder and at least 12 months of continuous enrollment (CE). The control population 
were year-, age- and sex-matched individuals with no mental health or substance abuse 
episodes and at least 12 months CE. A total of 102,670 cases and 205,340 controls 
were matched for the year 2006; 109,124 cases and 218,248 controls were matched 
in 2007. Treemaps produced by SAS v. 9.1 are used to convey the relative rankings 
of disease incidence and RR of disease as compared to persons without mental health 
disorders. RESULTS: Compared to controls, cases had elevated RR of disease ranging 
from 1.25 (conditions of the female reproductive system) to 3.14 (trauma or iatrogenic 
conditions). Among the speciﬁc trauma and iatrogenic conditions, poisoning, adverse 
drug reactions and injury the RRs at least 2.5 times higher than controls. Cases had 
a RR of 1.69 for endocrine and metabolic diseases (e.g diabetes, hypothyroidism, 
hypoglycemia). Musculoskeletal conditions and ear, nose and throat conditions were 
the most common types of physical comorbidities among both cases and controls, 
however, RR was 1.59 times higher for cases. CONCLUSIONS: Compared to patients 
with no mental health diagnoses, patients with bipolar disorder are at greater risk 
for a wide range of physical comorbidities. Treemaps are a valuable tool for visualizing 
the relative impact of a broad range of diseases across two populations.
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IMPACT OF COMORBIDITIES ON ANTIDEPRESSANT INITIATION: 
DULOXETINE, VENLAFAXINE, AND ESCITALOPRAM VERSUS  
OTHER SSRIS
Liu X1, Chen Y2, Faries D2, Miner C2, Swindle R1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: Although efﬁcacy and safety are 2 key issues to be taken into account 
when choosing an antidepressant, many other factors may also inﬂuence treatment 
initiation. The purpose of the study was to examine the impact of comorbidities on 
the initiation of antidepressants: duloxetine (DLX), valenfaxine (VLX), and escitalo-
pram (ECP) versus other SSRIs (OSSRI) in patients with major depressive disorder 
(MDD). METHODS: A total of 44,026 MDD patients from a large commercial 
administrative claims database were classiﬁed as initiators of DLX (n  7,567), VLX 
(n  6,106), ECP (n  10,239), or OSSRI (n  20,114) during the year 2006. Patients 
were classiﬁed on their ﬁrst index medication during the study period. All patients 
had no active prescription of the same medication(s) in the prior 3 months. On the 
basis of ICD-9-CM, 17 systemic disease classes and 21 individual diseases in the prior 
12 months were identiﬁed. RESULTS: Patients receiving DLX were more likely than 
those receiving VLX, ECP, and OSSRI to be female (75.1% vs. 71.5%, 69.7%, 70.5%, 
p  0.001) and aged 46 years or above (62.3% vs. 54.6%, 49.8%, 50.5%, p  0.001). 
Nearly all systemic disease classes and individual pain diseases were most prevalent 
in DLX patients, followed by VLX and ECP patients, with OSSRI patients being the 
least. Most signiﬁcant predicting comorbid diseases (OR  1.40) of DLX initiation 
versus OSSRI were ﬁbromyalgia (OR  1.86), low back pain (OR  1.54), and bipolar 
disorder (OR  1.43) after adjustment for demographics and other comorbidities. 
However, no comorbid diseases with an OR  1.40 were associated with VLX and 
ECP initiation versus OSSRI. CONCLUSIONS: Patients initiating DLX have the most 
comorbid diseases, followed by VLX, ECP, with patients initiating OSSRI having the 
least. Speciﬁcally, the presence of chronic pain diseases and bipolar disorder appear 
to be most signiﬁcant predictors of DLX initiation relative to OSSRI.
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EFFICACY OF ANTIPSYCHOTICS IN THE PREVENTION OF 
SCHIZOPHRENIA RELAPSE: A SYSTEMATIC REVIEW OF DOUBLE  
BLIND RANDOMISED CONTROLLED TRIALS
Meier G, Edwards SJ, von Maltzahn R
AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: Conduct a systematic review in schizophrenia relapse prevention, using 
the same methodology as the recent National Institute for Clinical Excellence (NICE) 
Schizophrenia Clinical Guideline. METHODS: Systematic review of CENTRAL, 
EMBASE, MEDLINE, for double-blind RCTs with, amisulpride, aripiprazole, olan-
zapine, paliperidone, quetiapine, risperidone, ziprasidone or zotepine, (completed 
November 2008). Relapse and withdrawal data were extracted using individual trial 
deﬁnitions. Mixed treatment comparison using Markov Chain Monte Carlo simula-
tion was conducted using a random effects model to estimate the risk of relapse, 
treatment discontinuation due to either intolerable adverse effects (DAE) or other 
reasons. Summary effect estimates are presented as Odd Ratios [OR] with 95% Cred-
ible Intervals (95%CrI) calculated versus placebo. RESULTS: Literature searching 
returned 488 papers that identiﬁed 18 RCTs that were of sufﬁcient quality to be 
included in the analysis. Relapse analysis reported quetiapine (XR) followed by ris-
peridone and zotepine as most effective: quetiapine (XR) (OR: 0.151, 95%CrI: 0.021, 
0.52), risperidone (OR: 0.168, 95%CrI: 0.035, 0.52), zotepine (OR: 0.17, 95%CrI: 
0.017, 0.69), olanzapine (OR: 0.225, 95%CrI: 0.081, 0.513), haloperidol (OR: 0.314, 
95%CrI: 0.075, 0.89), ziprasidone (OR: 0.315, 95%CrI: 0.079, 0.85), paliperidone 
(OR: 0.362, 95%CrI: 0.058, 1.214), amisulpride (OR: 0.387, 95%CrI: 0.041, 1.497), 
apriprazole (OR: 0.518, 95%CrI: 0.09, 1.702). Amisulpride, olanzapine and ziprasi-
done reported lowest OR for DAE. Amisulpride, quetiapine (XR) and olanzapine 
reported lowest OR for withdrawal due to other reasons, respectively. The model was 
considered a good ﬁt for relapse and discontinuation due other reasons but not for 
DAE. CONCLUSIONS: When NICE’s schizophrenia guideline was in production, 
quetiapine (XR) was not licensed in the UK and therefore excluded from the health 
economic model. However, it is now available and the above analysis suggests that 
treatment with quetiapine (XR) could potentially provide beneﬁt in the management 
of schizophrenia relapse prevention. No ﬁrm conclusions can be made from the 
 analysis DAE.
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CLINICAL EFFICACY AND SAFETY OF DULOXETINE IN COMPARISON 
WITH PLACEBO IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER  
IN POLAND
Pankiewicz O1, Jagodzinska K1, Rys P1, Lach K1, Jarczewska D1, Cel M2, Mierzejewski P2, 
Bartminski W3, Plisko R1, Wladysiuk M1
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OBJECTIVES: The objective of this analysis was to compare efﬁcacy and safety 
of duloxetine with placebo in the treatment of major depressive disorder in 
Poland. METHODS: Comparison was based on a systematic review, carried out 
according to guidelines published by the Cochrane Collaboration and the Agency 
for Health Technology Assessment in Poland. The most important medical databases 
(MEDLINE, EMBASE, CENTRAL) were searched. Two reviewers independently 
had selected trials, assessed their quality and extracted data. For efﬁcacy analysis 
improvements in Hamilton Rating Scale for Depression (HAM-D) and quality of 
life were measured. Percentage of patients responding to treatment (deﬁned as q50% 
improvement in HAM-D) and percentage of patients achieving total remission 
(deﬁned as a7 points HAM-D-17) were also reported. Head-to-head comparisons 
based on randomized controlled trials (RCTs) were performed both for safety and 
efﬁcacy analysis. RESULTS: The results of 14 RCTs were included in the analysis. 
After 7 to 9 weeks of treatment duloxetine allowed better improvement than 
placebo in HAM-D scores (WMD  2.26 [2.94; 1.57]) and in quality of life (WMD 
 3.60 [4.89; 2.31]). Percentage of patients with response to treatment (RB  1.42 
[1.29; 1.56]), NNT  6.95 [5.53; 9.37]), and with total remission (RB  1.45 [1.29; 
1.64]), NNT  8.92 [6.80; 12.93]) was also statistically signiﬁcantly higher for 
duloxetine group. Although risk of adverse events was signiﬁcantly higher in dulox-
etine treated patients (RR  1.19 [1.13; 1.24]; NNH  8.60 [6.75; 11.84]), no differ-
ences in the incidence of serious adverse events were observed (RR  0.95 [0.49; 1.84]). 
Withdrawals due to adverse events were signiﬁcantly more frequent in duloxetine 
group than in placebo group (RR  2.11 [1.61; 2.77], NNH  17.31 [12.87 26.44]). 
CONCLUSIONS: Duloxetine is efﬁcacious drug in the treatment of patients 
with major depressive disorder. Safety proﬁle seems to be acceptable (slightly worse 
than placebo).
PMH9
A SYSTEMATIC REVIEW OF PHARMACOLOGICAL TREATMENTS FOR 
BIPOLAR I MANIA
Parkinson BT1, von Maltzahn R2
1AstraZeneca UK Ltd, Luton, Bedfordshire, UK, 2AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: Update a previously published systematic review1 of pharmacological 
treatments for acute mania in bipolar I disorder, to include recent publications, includ-
ing new formulation quetiapine extended release (XR), and remission rates. 
METHODS: Systematic review of CENTRAL, EMBASE, MEDLINE, for randomised, 
controlled trials comparing placebo to: aripiprazole, carbamazepine, divalproex, halo-
peridol, lithium, olanzapine, quetiapine XR, and risperidone as monotherapy, in 
the treatment of acute mania in bipolar I disorder, published before March 2009. 
Trials of combination therapy and patients non-responsive to previous therapy were 
excluded. Data were combined through random effects meta-analyses using Compre-
hensive Meta Analysis. Summary effect estimates were presented as Relative Risk 
(RR) versus placebo and 95% Conﬁdence Interval (95%CI). RESULTS: 408 publica-
tions were identiﬁed and overall 19 trials from 18 papers were included in the analysis. 
The results for remission reported that risperidone followed by quetiapine XR were 
the most effective antipsychotics: risperidone (RR:1.87, 95%CI:1.22–2.85), quetiap-
ine XR (RR:1.46, 95%CI:1.07–2.01), olanzapine (RR:1.39, 95%CI:1.08–1.79), 
